MOLFETTA, Rosa
 Distribuzione geografica
Continente #
NA - Nord America 3.117
EU - Europa 1.808
AS - Asia 758
SA - Sud America 266
AF - Africa 58
Continente sconosciuto - Info sul continente non disponibili 4
Totale 6.011
Nazione #
US - Stati Uniti d'America 3.089
IT - Italia 816
DE - Germania 276
SG - Singapore 259
BR - Brasile 212
CN - Cina 185
SE - Svezia 162
IN - India 158
FI - Finlandia 101
NL - Olanda 79
RU - Federazione Russa 78
FR - Francia 74
UA - Ucraina 73
GB - Regno Unito 62
TG - Togo 30
KR - Corea 28
AR - Argentina 27
BG - Bulgaria 27
ID - Indonesia 25
CA - Canada 19
IR - Iran 16
TR - Turchia 13
HK - Hong Kong 12
BE - Belgio 11
VE - Venezuela 11
IE - Irlanda 10
RO - Romania 9
AT - Austria 8
ZA - Sudafrica 8
JO - Giordania 7
JP - Giappone 7
MA - Marocco 7
UZ - Uzbekistan 7
AL - Albania 6
IQ - Iraq 6
TW - Taiwan 6
AE - Emirati Arabi Uniti 5
BD - Bangladesh 5
CH - Svizzera 5
NP - Nepal 5
PY - Paraguay 5
ES - Italia 4
MX - Messico 4
CL - Cile 3
EC - Ecuador 3
NG - Nigeria 3
PA - Panama 3
PK - Pakistan 3
TN - Tunisia 3
XK - ???statistics.table.value.countryCode.XK??? 3
BO - Bolivia 2
DZ - Algeria 2
IL - Israele 2
KE - Kenya 2
KZ - Kazakistan 2
PE - Perù 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
CG - Congo 1
CO - Colombia 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EU - Europa 1
GR - Grecia 1
HN - Honduras 1
KG - Kirghizistan 1
KH - Cambogia 1
LB - Libano 1
LT - Lituania 1
MK - Macedonia 1
MU - Mauritius 1
NO - Norvegia 1
PH - Filippine 1
PS - Palestinian Territory 1
PT - Portogallo 1
SN - Senegal 1
TH - Thailandia 1
Totale 6.011
Città #
Fairfield 404
Ashburn 371
Rome 371
Woodbridge 207
Chandler 204
Singapore 175
Seattle 158
Dearborn 146
Houston 146
Wilmington 135
Cambridge 126
Ann Arbor 121
Santa Clara 120
Princeton 74
Paris 66
Fasano 61
Plano 58
San Paolo di Civitate 55
Helsinki 49
Washington 48
Lawrence 43
Munich 40
Millbury 34
Beijing 33
Lomé 30
Boston 29
Milan 28
New York 28
Sofia 27
Jakarta 25
Moscow 22
Jacksonville 21
Andover 19
San Diego 19
Des Moines 17
Federal 16
Hefei 16
Toronto 14
São Paulo 13
Naples 12
Bremen 11
Brussels 11
Latina 11
Nanjing 11
Norwalk 11
Phoenix 11
Boardman 10
Dublin 10
Falls Church 10
Fremont 10
London 9
San Jose 9
Bühl 8
Falkenstein 8
Kunming 8
Leawood 8
Ramsgate 8
Amman 7
Hangzhou 7
Key Biscayne 7
Parma 7
Pune 7
Sacramento 7
Tashkent 7
Tehran 7
Brasília 6
Istanbul 6
Los Angeles 6
Shanghai 6
Amsterdam 5
Belo Horizonte 5
Chennai 5
Curitiba 5
Dongjak-gu 5
Fiuggi 5
Grafing 5
Maracaibo 5
Monterotondo 5
Moraga 5
San Mateo 5
Southend 5
Tivoli 5
Zanjan 5
Ancona 4
Arezzo 4
Artena 4
Auburn Hills 4
Campinas 4
Cape Town 4
Castel Gandolfo 4
Cormano 4
Goiânia 4
Hong Kong 4
Lafayette 4
Manchester 4
Nuremberg 4
Seongbuk-gu 4
Taipei 4
Vienna 4
Atlanta 3
Totale 3.962
Nome #
Immune complexes exposed on mast cell-derived nanovesicles amplify allergic inflammation 210
Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: role of HSP70/TLR2/NF-kB axis 168
p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells 166
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells. role of cMYC-IRF4-miR-125b interplay 159
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma 150
Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA. Dual role in cancer immunosurveillance 144
Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation 139
Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms 129
3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cells 124
The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in multiple myeloma. modulation by bromodomain and Extra-Terminal (BET) protein inhibitors 122
Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells 118
Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production 116
The adaptor molecule CIN85 regulates Syk tyrosine kinase level by activating the ubiquitin-proteasome degradation pathway 114
NKG2D and its ligands: one for all, all for one 105
Bone marrow stromal cell-derived IL-8 upregulates PVR expression on multiple myeloma cells via NF-kB transcription factor 105
c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells. 99
Translating the anti-myeloma activity of Natural Killer cells into clinical application 98
Regulation of NKG2D Expression and Signaling by Endocytosis 95
Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition 93
null 92
Regulation of fc receptor endocytic trafficking by ubiquitination. 92
Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells 91
Ubiquitination and endocytosis of the high affinity receptor for IgE. 89
CIN85 regulates the ligand-dependent endocytosis of the IgE receptor: A new molecular mechanism to dampen mast cell function 89
NK cells and interferons 88
Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells 87
The Cbl family of ubiquitin ligases regulates FcεRI expression and mast cell activation. 83
Negative regulation of FcepsilonRI-mediated basophil activation by the Cbl family of adaptor proteins. 82
Syk-dependent regulation of Hrs phosphorylation and ubiquitination upon FceRI engagement: Impact on Hrs membrane/cytosol localization 82
PIP2-dependent regulation of Munc13-4 endocytic recycling: impact on the cytolytic secretory pathway 82
Syk regulates ligand-induced FcepsilonRI down-modulation and degradation in mast cells 81
CD155: a multi-functional molecule in tumor progression 81
Ubiquitin and ubiquitin-like modifiers modulate NK cell-mediated recognition and killing of damaged cells 79
The adaptor molecule CIN85 regulates Syk tyrosine kinase level by activating the ubiquitin-proteasome degradation pathway. 77
Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation 75
A sustained CD16 aggregation induced by therapeutic antibody-opsonised targets impairs cytotoxic responses in human NK cells 73
Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis. 73
FcepsilonRI engagement induces negative pathways that attenuate receptor-mediated mast cell signalling and functions 72
Post-translational mechanisms regulating NK cell activating receptors and their ligands in cancer: Potential targets for therapeutic intervention 71
CIN85 controls the down-regulation of engaged FcepsilonRI providing a new molecular mechanism to dampen mast cell function 68
Ubiquitination and degradation of Syk and ZAP-70 protein tyrosine kinases in human NK cells upon CD16 engagement 68
Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia 65
Cbl Family Proteins: Balancing Fc epsilon RI-Mediated Mast Cell and Basophil Activation 65
NK Cells and Other Cytotoxic Innate Lymphocytes in Colorectal Cancer Progression and Metastasis 63
null 62
Syk kinase activity regulates endocytosis of ubiquitinated FcεRI 60
NKG2D engagement on human NK cells leads to DNAM‐1 hypo‐responsiveness through different converging mechanisms 59
CIN85 regulates the ligand-induced internalization of the high affinity receptor for IgE: a new mechanism to attenuate mast cell functions 59
NKG2D down-modulation on human NK cells is followed by DNAM-1 hypo-responsivenss 58
Tyrosine kinase-dependent ubiquitination of CD16 zeta subunit in human NK cells following receptor engagement. 58
Samhd1 phosphorylation and cytoplasmic relocalization after human cytomegalovirus infection limits its antiviral activity 55
Syk kinase activity controls the coupling of engaged FcepsilonRI to the endocytic pathway 52
Impact of SARS-CoV-2 vaccination on FcγRIIIA/CD16 dynamics in Natural Killer cells: relevance for antibody-dependent functions 49
Negative signal from FcepsilonRI engagement attenuate mast-cell functions. 49
Activation of Syk tyrosine kinase is required for c-Cbl-mediated ubiquitination of Fcepsilon RI and Syk in RBL cells. 47
Lipid raft-dependent FcepsilonRI ubiquitination controls endocytosis of engaged receptors in mast cells 47
FcεRI signaling in the modulation of allergic response: role of mast cell-derived exosomes 47
CD16 aggregation induced by therapeutic antibody-opsonised targets impairs cytotoxic responses in human NK cells 47
The Controversial Role of Intestinal Mast Cells in Colon Cancer 46
SCF and IL-33 regulate mouse mast cell phenotypic and functional plasticity supporting a pro-inflammatory microenvironment 45
Lipid raft-dependent FcepsilonRI ubiquitination regulates receptor endocytosis through the action of ubiquitin binding adaptors. 45
Tyrosine kinase-dependent multiubiquitination of CD16 zeta subunit in human NK cells following receptor engagement 45
CD16 engagement induces ubiquitination and degradation of Syk and ZAP-70 tyrosine kinases in human NK cells 44
null 44
Understanding the role of mast cells in colorectal cancer progression 43
New Insight into Intestinal Mast Cells Revealed by Single-Cell RNA Sequencing 42
Regulation of MICB shedding from multiple myeloma cells in response to genotoxic stress. 41
Down-regulation of the NKG2D receptor is differentially controlled by MICA and ULBP2 ligands 40
Endocitosi del recettore ad alta affinità per le IgE sui mastociti: conseguenze funzionali 39
Colorectal Cancer microenvironment controls Mast Cell phenotypical plasticity 38
Lipid raft-dependent FcepsilonRI ubiquitination regulates endocytosis of engaged receptors in mast cells 37
Syk kinase activity regulates endocytosis of ubiquitinated FcepsilonRI on mast cells 37
REGULATION OF BCR SIGNALLING IN CHRONIC LYMPHOCITYC LEUKEMIA: ROLE OF E3 UBIQUITIN LIGASE C-CBL 37
NKG2D receptor expression is differentially controlled by MICA e ULBP2 ligands 35
Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells 35
Negative signals from FcepsilonRI engagement attenuate receptor-mediated mast cell functions 34
Exploring mast cell phenotype and functions during tumor progression 32
Connective tissue-like Mast Cells accumulate during Colorectal Cancer progression 31
NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells 28
The Ubiquitin-proteasome pathway regulates Nectin2/CD112 expression and impairs NK cell recognition and killing. 25
NGF-dependent and tissue-specific transcription of vgf is regulated by a CREB-p300 and bHLH factor interaction. 24
SUMOylation and related post-translational modifications in natural killer cell anti-cancer responses 22
SCF and IL-33 regulate mouse mast cell pro-inflammatory functions during tumor progression 22
Analysis of infiltrating MC subsets in Colorectal cancer by single-cell RNA-sequencing. 22
Optimizing transfection efficiency in CAR-T cell manufacturing through multiple administrations of lipid-based nanoparticles 22
Meccanismi implicati nello spegnimento delle vie di segnalazione mediate dal recettore ad alta affinità per le IgE (FcepsilonRI) 21
SCF and IL-33 regulate intestinal mouse mast cell plasticity in colon cancer 21
null 19
MICA and ULBP2 differentially regulate NKG2D cell surface expression 19
Dysregulation of DNAM-1-Mediated NK Cell Anti-Cancer Responses in the Tumor Microenvironment 12
Nutrient transporter pattern in CD56dim NK cells: CD16 (FcγRIIIA)-dependent modulation and association with memory NK cell functional profile 6
CD155 and Its Receptors as Targets for Cancer Therapy 5
null 4
Totale 6.233
Categoria #
all - tutte 18.188
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.188


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020587 0 0 0 0 0 0 172 111 123 98 47 36
2020/2021571 30 50 20 26 13 20 70 23 36 181 38 64
2021/2022726 1 45 102 45 93 16 22 76 57 49 97 123
2022/2023970 182 272 45 81 83 96 13 55 52 2 61 28
2023/2024854 27 66 70 84 102 199 41 38 10 89 48 80
2024/20251.144 82 54 65 140 198 304 301 0 0 0 0 0
Totale 6.233